Karyo takes H&E histology images and marks mitotic figures, cells caught mid-division, as points. Pathologists count these to grade tumours.
The core problem is domain shift. Evaluation is leave-one-tumour-type-out: train on six tumour types, test on a seventh the model has never seen, across species, labs and scanners.
It exists to find out how far a small, hand-built model gets on a domain it has never seen. It is a research model on a public benchmark, MIDOG++. It is not a diagnostic tool.
The name: karyon, Greek for nucleus, and karyokinesis, the nucleus dividing.